FRANKLIN LAKES, N.J., Dec. 22, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BD BD is one of the ...

The Company and Embecta entered into various agreements to effect the spin-off and provide a framework for the relationship between the Company and Embecta after the spin-off. Such agreements include the separation and distribution agreement, as well as the following ongoing agreements: a cannula supply agreement, an intellectual property matters agreement, a transition services agreement, manufacturing and 64 Table of Contents Notes to Consolidated Financial Statements — (Continued) Becton, Dickinson and C ...

Becton, Dickinson and Company (NYSE:BDX) Q43 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen – Chairman, President and Chief Executive Officer Chris DelOrefice – Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Matt Miksic - Barclays Operator Hel ...

Becton, Dickinson and Company (NYSE:BDX) Q3 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Francesca DeMartino – Senior Vice President-Investor Relations Tom Polen – Chairman, President and Chief Executive Officer Chris DelOrefice – Executive Vice President and Chief Financial Officer Mike Garrison – President-Medical Segment Dave Hickey – President-Life Sciences Segment Conference Call Participants Vijay Kumar – Evercore ISI Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorg ...

| --- | --- | --- | |----------------------------------------------|-----------|-------------------------| | | | | | | | | | Q3 FY23 Earnings Presentation August 3, 2023 | | | | | | | | | Advancing | the world of health TM | Caution Concerning Forward-Looking Statements This presentation and accompanying audio webcast contain certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future ...

Financial Performance - For the three months ended June 30, 2023, net income from continuing operations was $407 million, with diluted earnings per share of $1.36, compared to $390 million and $1.28 for the same period in 2022, representing a 4.4% increase in net income [145]. - The gross profit margin for the three months ended June 30, 2023, was 43.1%, down from 44.5% in the same period of 2022, primarily due to purchase accounting adjustments and foreign currency translation impacts [141]. - Operating cash flows for the nine months ended June 30, 2023, were $1,665 million, an increase from $1,498 million for the same period in 2022, reflecting improved operational efficiency [145]. - The company reported a total of $2,252 million in trade receivables for the nine months ended June 30, 2023, compared to the previous year's $1,000 million, showing a substantial growth in receivables [133]. - Emerging markets revenue for the three months ended June 30, 2023, was $773 million, a 9.9% increase from $703 million in the same period of 2022, with a foreign exchange neutral change of 13.8% [139]. Investment and Cash Flow - Trade receivables transferred to third parties under factoring arrangements amounted to $762 million for the three months ended June 30, 2023, compared to $215 million for the same period in 2022, indicating a significant increase in factoring activity [133]. - The net cash used for investing activities for the nine months ended June 30, 2023, was $(853) million, compared to $(1,215) million for the same period in 2022, indicating a reduction in cash outflows for investments [145]. - The company has a maximum of 8,799,998 shares that may yet be purchased under publicly announced plans or programs as of June 30, 2023 [255]. Strategic Outlook and Growth - The company anticipates continued growth in volume and pricing, with a focus on future product development and regulatory approvals as part of its strategic outlook [153]. Risks and Challenges - The company faces risks related to overall indebtedness, including the ability to service and refinance debt, which is influenced by capital markets and macroeconomic conditions [261]. - Changes in healthcare delivery, including a shift from acute to non-acute settings and a focus on chronic disease management, may impact demand for the company's products and services [261]. - Regulatory scrutiny on sterilization processes, particularly concerning ethylene oxide, could adversely affect the company's manufacturing capabilities and supply chain [261]. - The company is operating under a Consent Decree with the FDA for its U.S. infusion pump business, which may impact the timing of product replacements and market re-entry [261]. - The ongoing COVID-19 pandemic, including potential resurgences and government restrictions, may disrupt operations and affect product demand [261]. - Changes in reimbursement practices by governments or third-party payers could reduce demand for the company's products or affect pricing [261]. - The company is exposed to international market conditions, including geopolitical developments and compliance risks, which could impact operations [261]. - Adverse media exposure could negatively affect the company's reputation and product demand [262]. - Market fluctuations may impact the value of assets in the company's pension plans, potentially increasing pension plan expenses [262]. - The company may face challenges in realizing anticipated benefits from any restructuring programs undertaken [262].

| --- | --- | |-------------------------------------------|-------------------------------------| | | | | | | | Q2 FY23 Earnings Presentation May 4, 2023 | | | | Advancing the world of health TM | Caution Concerning Forward-Looking Statements This presentation contains certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets a ...

Becton, Dickinson and Company (NYSE:BDX) Q2 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Francesca DeMartino - Senior Vice President and Head-Investor Relations Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Mike Garrison - President-Medical Segment Rick Byrd - President of the Interventional segment Dave Hickey - President-Life Sciences Segment Conference Call Participants Robbie Marcus - JPMor ...

Cash flows from continuing operating activities in the first six months of fiscal year 2023 reflected net income, adjusted by a change in operating assets and liabilities that was a net use of cash. This net use of cash primarily reflected lower levels of accounts payable and accrued expenses, as well as higher levels of inventory and trade receivables. Cash flows from continuing operating activities in the first six months of fiscal year 2022 reflected net income, adjusted by a change in operating assets a ...

TD Cowen 43rd Annual Health Care Conference March 6, 2023 Tom Polen Chairman, CEO, and President Caution Concerning Forward-Looking Statements This presentation contains certain estimates and other forward-looking statements (as defined under federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations of BD and involve a n ...